<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715360</url>
  </required_header>
  <id_info>
    <org_study_id>20-12-1526</org_study_id>
    <nct_id>NCT04715360</nct_id>
  </id_info>
  <brief_title>Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy</brief_title>
  <official_title>Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hayandra Peduli Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koja Regional Public Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hayandra Peduli Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing&#xD;
      rapidly since the first case found in March 2020 to date. Coronavirus 2 (SARS-CoV-2) virus&#xD;
      disrupts human normal immune system resulting in uncontrolled inflammatory response. Based on&#xD;
      our research and experience in doing cell therapy for 9 years, activated platelet-rich plasma&#xD;
      (PRP) produces anti-inflammatory effects in inflammatory condition that is beneficial for&#xD;
      tissue regeneration. In this study, we aimed to evaluate the potential of autologous&#xD;
      activated platelet-rich plasma (aaPRP) and the outcomes for treating severe Coronavirus&#xD;
      Disease-2019 (COVID-19) patients in Intensive Care Unit (ICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRP decreases IL-1β, IL-6, IL-8, and TNFα inflammatory genes expression while also reduces&#xD;
      IL-1β and TNFα inflammatory cytokines production. PRP has also been showed to contain&#xD;
      interleukin 1 receptor antagonist (IL-1RA), an anti-inflammatory cytokines that suppress IL-6&#xD;
      secretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 27, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of aaPRP on pro-inflammatory cytokines plasma level (IL-6, IL-1B, TNFa, IFN gamma, MCP-1) before and after intervention compared to control.</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to evaluate the change of Effect of aaPRP on anti-inflammatory cytokines plasma level (IL-1RA, IL-4, IL-10) before and after intervention compared to control.</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of aaPRP on overall adverse event related to the treatment.</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of aaPRP on CRP level before and after intervention compared to control.</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of aaPRP on Thorax X-ray image pre and post intervention between control and aaPRP-treated group</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of aaPRP on duration of hospitality of patient compared to control</measure>
    <time_frame>6 days</time_frame>
    <description>Patients with positive COVID19 who will improve after receiving aaPRP compared to control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Covid19</condition>
  <condition>Sars-CoV-2 Infection</condition>
  <condition>ARDS, Human</condition>
  <condition>Severe covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Only received standard medication (avigan) for severe COVID-19 management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received standard medication (avigan) for severe COVID-19 management and autologous activated platelet-rich plasma transfusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>autologous activated platelet-rich plasma</intervention_name>
    <description>Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient</description>
    <arm_group_label>PRP Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avigan</intervention_name>
    <description>Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PRP Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  severe covid-19 patient in ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CKD on hemodialysis, HIV positive, hepatitis, pregnant, destroyed lung, cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis Martin Christoffel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Koja Regional Public Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karina Karina, MD, PhD</last_name>
    <phone>62.21.3909333</phone>
    <email>karina@hayandra.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imam Rosadi, M.Sc</last_name>
    <phone>6285719593848</phone>
    <email>imam.rosadi@hayandra.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Koja Regional Public Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>14220</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Martin Christoffel, MD</last_name>
      <phone>6281340062037</phone>
      <email>louischristoffel200@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 17, 2021</last_update_submitted>
  <last_update_submitted_qc>January 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aaPRP</keyword>
  <keyword>severe COVID-19</keyword>
  <keyword>platelet-rich plasma</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

